Emergex Vaccines has secured $11 million funding.
Abingdon biotechnology company firm develops set-point vaccines to prevent some of the world鈥檚 most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic flu.
The Series A round was led by Vickers Venture Partners. Dr Finian Tan, chairman of Vickers Venture Partners, has joined Emergex鈥檚 board of directors.
Professor Thomas Rademacher, CEO and co-founder of Emergex, commented: 鈥淎ttracting such high calibre investors is an endorsement of our development pipeline and validation of the potential our technologies hold in the field of infectious diseases.
鈥淭hese new funds will support us to achieve some significant value-enhancing milestones as we progress our lead vaccine candidates into clinical development.鈥�
Emergex鈥檚 underlying platform technology enables rapid development of vaccines to entire families of pathogens, compared to traditional approaches that can take years to develop and scale vaccines for single pathogens.
As purely synthetic vaccines with no biological components, Emergex鈥檚 vaccines are much safer as they carry no infection risk from live attenuated pathogens; are much cheaper to produce since they do not require culturing; and can be conveniently transported and administered even in remote parts of the world as they can be stored and handled at room temperature.